RE:RE:RE:RE:RE:New Press Release - Theratechnologies Announces Path to Resume TH1902 Clinical Development On the previous corporate presentation they did say their intention were to restart the trial in first half of 2023 so if the SAC finalize the amended protocol by end of next month, and it get submitted "promptly" then add the 30 day period for the FDA to approve it they should be able to restart it in the first half of the 2023. The only new news is the identity of the SAC members and now "patient selection".
What I don't understand is when they say path to resume.... one would like to know more detailed information otherwise what was the purpose of the PR? It would be better to wait few weeks and once the protocol is finalized then issue a PR with more details about dosing strategies and patient selection. I think they need to understand after the sudden pause followed by the some 50 or 60 percent decrease of the valuation of the company they have to explain the "path" more in details. Why different dosing strategies and now patient selection can increase the chances of a successful outcome?